Clinuvel drug kicks off EU project to boost patient role in benefit-risk review
This article was originally published in Scrip
Executive Summary
In a move intended to give patients more of a say in the evaluation of new drugs, the European Medicines Agency has begun a project under which patients will be invited to take part in certain benefit-risk discussions at meetings of its main scientific committee, the CHMP. The project has kicked off with Clinuvel's Scenesse (afamelanotide), a new drug intended to treat the rare disease erythropoietic protoporphyria (EPP).
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.